Treosulfan
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Treosulfan |
| DrugBank ID | DB11678 |
| Brand Names (EU) | Trecondi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.01% |
Approved Indication (EMA)
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | diabetic cataract | 99.01% | DL |
| 2 | cortical cataract | 98.96% | DL |
| 3 | nuclear senile cataract | 98.96% | DL |
| 4 | immature cataract | 98.95% | DL |
| 5 | craniostenosis cataract | 98.95% | DL |
| 6 | tetanic cataract | 98.95% | DL |
| 7 | diabetes mellitus type 2 associated cataract | 98.95% | DL |
| 8 | mature cataract | 98.95% | DL |
| 9 | diabetic retinopathy | 98.93% | DL |
| 10 | senile cataract | 98.92% | DL |
| 11 | severe nonproliferative diabetic retinopathy | 98.90% | DL |
| 12 | odontogenic cyst | 96.61% | DL |
| 13 | bronchial adenomas/carcinoids childhood | 96.60% | DL |
| 14 | chondroid hamartoma | 96.60% | DL |
| 15 | ductal or ductular proliferation | 96.60% | DL |
| 16 | non-seminomatous lesion | 96.60% | DL |
| 17 | pre-malignant neoplasm | 96.58% | DL |
| 18 | tumor of testis and paratestis | 96.56% | DL |
| 19 | thyroglossal duct cyst | 96.53% | DL |
| 20 | nasopharyngeal teratoma | 96.52% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.